Last reviewed · How we verify

MenACYW-135 conjugate vaccine — Competitive Intelligence Brief

MenACYW-135 conjugate vaccine (MenACYW-135 conjugate vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Conjugate vaccine. Area: Immunology / Infectious Disease.

phase 3 Conjugate vaccine Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

MenACYW-135 conjugate vaccine (MenACYW-135 conjugate vaccine) — Sanofi Pasteur, a Sanofi Company. MenACYW-135 is a conjugate vaccine that stimulates the immune system to produce antibodies against meningococcal serogroups A, C, Y, and W-135.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
MenACYW-135 conjugate vaccine TARGET MenACYW-135 conjugate vaccine Sanofi Pasteur, a Sanofi Company phase 3 Conjugate vaccine
Prevnar 20 pneumococcal 20-valent conjugate vaccine (PCV20) Pfizer Inc. marketed Pneumococcal conjugate vaccine Streptococcus pneumoniae capsular polysaccharides (20 serotypes) 2021-06-08
A+C Vaccine A+C Vaccine Jiangsu Province Centers for Disease Control and Prevention marketed Polysaccharide conjugate vaccine Neisseria meningitidis serogroups A and C polysaccharide capsule
Meningococcal C Meningococcal C Wyeth is now a wholly owned subsidiary of Pfizer marketed Conjugate vaccine Neisseria meningitidis serogroup C polysaccharide capsule
Comparator: PedvaxHIB™ Comparator: PedvaxHIB™ Merck Sharp & Dohme LLC marketed Conjugate vaccine Haemophilus influenzae type b polyribosylribitol phosphate (PRP) capsular polysaccharide
Meningococcal A+C vaccine Meningococcal A+C vaccine Sanofi Pasteur, a Sanofi Company marketed Polysaccharide conjugate vaccine Neisseria meningitidis serogroups A and C capsular polysaccharides
PCV10 full dose PCV10 full dose Epicentre marketed Pneumococcal conjugate vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (Conjugate vaccine class)

  1. GlaxoSmithKline · 26 drugs in this class
  2. Sanofi Pasteur, a Sanofi Company · 6 drugs in this class
  3. CanSino Biologics Inc. · 3 drugs in this class
  4. MCM Vaccines B.V. · 3 drugs in this class
  5. Beijing Minhai Biotechnology Co., Ltd · 3 drugs in this class
  6. Wyeth is now a wholly owned subsidiary of Pfizer · 2 drugs in this class
  7. PT Bio Farma · 2 drugs in this class
  8. LG Life Sciences · 2 drugs in this class
  9. Walvax Biotechnology Co., Ltd. · 2 drugs in this class
  10. Heinrich-Heine University, Duesseldorf · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MenACYW-135 conjugate vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/menacyw-135-conjugate-vaccine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: